Recent developments in the treatment of uveitis: An update

Expert Opinion on Investigational Drugs

Volumn 18, Issue 5, 2009, Pages 609-616

  Lyon, Fiona ^b   Gale, Richard P ^b   Lightman, Susan ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b YORK HOSPITAL   (United Kingdom)

Author keywords

Biologics; Corticosteroids; Treatment; Uveitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEMTUZUMAB; ALPHA2A INTERFERON; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DEXAMETHASONE; EFALIZUMAB; ETANERCEPT; FLUOCINOLONE ACETONIDE; FLUOROMETHOLONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LOTEPREDNOL ETABONATE; METHOTREXATE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIMEXOLONE; RITUXIMAB; TACROLIMUS; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOCLOSPORIN;

ADRENAL INSUFFICIENCY; AMENORRHEA; AUTOIMMUNE DISEASE; BEHCET DISEASE; BODY WEIGHT; BONE MARROW SUPPRESSION; CATARACT; DEPRESSION; DIABETES MELLITUS; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOPHTHALMITIS; ERECTILE DYSFUNCTION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEMOLYTIC ANEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMPLANT; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; LIVER TOXICITY; LUPUS LIKE SYNDROME; MOOD; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OSTEOPOROSIS; PANCREATITIS; PATHOGENESIS; POSTPRIMARY TUBERCULOSIS; PTOSIS; RASH; RETINA MACULA CYSTOID EDEMA; REVIEW; SIDE EFFECT; SOFT TISSUE INFECTION; TESTIS ATROPHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; UVEITIS; WEGENER GRANULOMATOSIS;

ADRENAL CORTEX HORMONES; ANIMALS; DRUG DISCOVERY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME; UVEITIS;

EID: 67649604216     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220902852570     Document Type: Review

References (69)

1. Jabs DA. Epidemiology of uveitis. Ophthalmic Epidemiol 2008;15:283-284
2. Jabs D, Nussenblatt R, Rosenbaum J; SoUNSW Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-516 (Pubitemid 41224845)
3. Yeh S, Faia LJ, Nussenblatt RB. Advances in the diagnosis and immunotherapy for ocular inflammatory disease. Semin Immunopathol 2008;30:145-164
4. Gritz D, Wong I. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004;111:491-500 (Pubitemid 38293104)
5. Williams G, Brannan S, Forrester J, et al. The prevalence of sight-threatening uveitis in Scotland. Br J Ophthalmol 2007;91:33-36 (Pubitemid 46094004)
6. Suttorp-Schulten M, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996;80:844-848 (Pubitemid 26345317)
7. Rothova A, Schulten MSV, Treffers WF, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-336 (Pubitemid 26113585)
8. Schäcke H, Döcke W, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43 (Pubitemid 35346616)
9. Biswas J, Ganeshbabu T, Raghavendran S, et al. Efficacy and safety of 1% rimexolone versus 1% prednisolone acetate in the treatment of anterior uveitis - a randomized triple masked study. Int Ophthalmol 2004;25:147-153
10. Ferrante P, Ramsey A, Bunce C, Lightman S. Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Experiment Ophthalmol 2004;32:563-568 (Pubitemid 40074099)
11. Özkiris A. Intravitreal triamcinolone acetonide injection for the treatment of posterior uveitis. Ocul Immunol Inflamm 2006;14:233-238 (Pubitemid 44266801)
12. Kok H, Lau C, Maycock N, et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005;112:1916.e1-7
13. Galor A, Margolis R, Brasil O, et al. Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology 2007;114:1912-1918
14. Sallam A, Comer R, Chang J, et al. Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthalmol 2008;126:200-205
15. Roth D, Flynn H. Distinguishing between infectious and noninfectious endophthalmitis after intravitreal triamcinolone injection. Am J Ophthalmol 2008;146:346-347
16. Kuppermann B, Blumenkranz M, Haller J, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-317
17. Jaffe G, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-1027
18. Jaffe G. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis. Am J Ophthalmol 2008;145:667-675
19. MUST trial inclusion criteria. Available from: http://www.nei.nih.gov/ neitrials/viewStudyWeb.aspx?id=106 [Last accessed 25 October 2008]
20. Callanan D, Jaffe G, Martin D, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008;126:1191-1201
21. Hemady R, Chan A, Nguyen A. Immunosuppressive agents and nonsteroidal anti-inflammatory drugs for ocular immune and inflammatory disorders. Ophthalmol Clin North Am 2005;18:511-528,vi (Pubitemid 41728020)
22. Rabiah P, Fiscella R, Tessler H. Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Invest Ophthalmol Vis Sci 1996;37:613-618 (Pubitemid 26077681)
23. Menezo V, Lau C, Comer M, Lightman S. Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis. Clin Exp Ophthalmol 2005;33:16-21 (Pubitemid 40330970)
24. Galor A, Jabs D, Leder H, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008;115:1826-1832
25. Imrie F, Dick A. Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis. Curr Opin Ophthalmol 2007;18:212-219 (Pubitemid 46624919)
26. Braun J, Kästner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008;58:73-81
27. Compagni A, Bartoli S, Buehrlen B, et al. Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects. Int J Technol Assess Health Care 2008;24:294-302 (Pubitemid 351950165)
28. Payne K, Newman W, Fargher E, et al. TPMT testing in rheumatology: any better than routine monitoring? Rheumatology (Oxf) 2007;46:727-729
29. Fargher E, Tricker K, Newman W, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther 2007;32:187-195 (Pubitemid 46449703)
30. Teoh S, Hogan A, Dick A, Lee R. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol 2008;146:752-60,60.e1-3
31. Cervantes-Castaneda R, Bhat P, Huynh N, et al. The role of azathioprine in the treatment of ocular inflammatory disease: a six month follow-up analysis [abstract 5822]. Program and abstracts of the Association for Research in Vision and Ophthalmology (ARVO) 2008
32. Hogan A, McAvoy C, Dick A, Lee R. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007;114:100-106 (Pubitemid 46635862)
33. Murphy C, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005;123:634-641
34. Cunningham M, Austin B, Li Z, et al. LX211 (voclosporin) suppresses experimental uveitis and inhibits human T-cells. Invest Ophthalmol Vis Sci 2009;50(1):249-255
35. Papp K, Bissonnette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008;371:1337-1342
36. Goldstein D, Fontanilla F, Kaul S, et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology 2002;109:370-377
37. Imai Y, Ohno S. Helper T-cell subsets in uveitis. Int Ophthalmol Clin 2002;42:25-32 (Pubitemid 34075975)
38. Dick A. Immune mechanisms of uveitis: insights into disease pathogenesis and treatment. Int Ophthalmol Clin 2000;40:1-18 (Pubitemid 30235938)
39. Imrie F, Dick A. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007;18:481-486 (Pubitemid 351339402)
40. Dick A, Carter D. Cytokines and immunopathogenesis of intraocular posterior segment inflammation. Ocul Immunol Inflamm 2003;11:17-28 (Pubitemid 36918642)
41. Trinh L, Brignole-Baudouin F, Raphael M, et al. Th1 and Th2 responses on the ocular surface in uveitis identified by CCR4 and CCR5 conjunctival expression. Am J Ophthalmol 2007;144:580-585 (Pubitemid 47429616)
42. Luger D, Caspi R. New perspectives on effector mechanisms in uveitis. Semin Immunopathol 2008;30:135-143
43. Ke Y, Sun D, Zhang P, et al. Suppression of established experimental autoimmune uveitis by anti-LFA-1alpha Ab. Invest Ophthalmol Vis Sci 2007;48:2667-2675
44. Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008;159:513-526
45. Tzu J, Kerdel F. From conventional to cutting edge: the new era of biologics in treatment of psoriasis. Dermatol Ther 2008;21:131-141
46. Sobrin L, Kim E, Christen W, et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007;125:895-900
47. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001;358:295-296
48. Wallis R. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 2008;58:947-952 (Pubitemid 351563995)
49. Murray P, Sivaraj R. Anti-TNF alpha therapy for uveitis: Behcet and beyond. Eye 2005;19:31-33 (Pubitemid 41195133)
50. Lindstedt E, Baarsma G, Kuijpers R, Hagen PV. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005;89:533-536 (Pubitemid 40569703)
51. Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 2006;33:231-237
52. Galor A, Perez V, Hammel J, Lowder C. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317-2323 (Pubitemid 44838928)
53. Lim L, Fraunfelder F, Rosenbaum J. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-3252 (Pubitemid 47585419)
54. Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxf) 2008;47:339-344
55. Gallagher M, Quinones K, Cervantes-Castañeda R, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007;91:1341-1344 (Pubitemid 47492870)
56. Nussenblatt R, Peterson J, Foster C, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005;112:764-770
57. Yang D, Taylor S, Lightman SL. Interferon-alpha in the management of patients with Behçet's disease. Br J Hosp Med 2008;69:575-579
58. Plskova J, Greiner K, Forrester J. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007;144:55-61 (Pubitemid 46963200)
59. Plskova J, Greiner K, Muckersie E, et al. Interferon-alpha: a key factor in autoimmune disease? Invest Ophthalmol Vis Sci 2006;47:3946-3950
60. Dick A, Meyer P, James T, et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000;84:107-109 (Pubitemid 30251643)
61. Manadan A, Block J. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade. Am J Ther 2008;15:53-58 (Pubitemid 351161182)
62. Tappeiner C, Heinz C, Specker C, Heiligenhaus A. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007;39:184-186 (Pubitemid 46975985)
63. Taylor S, Salama A, Pusey C, Lightman S. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2008
64. Manadan A, Block J. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade. Am J Ther 2008;15:53-58 (Pubitemid 351161182)
65. Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis - a case report. J Rheumatol 2008;35:1897-1898
66. Bingham C 3rd. Emerging therapeutics for rheumatoid arthritis. Bull Hosp Jt Dis 2008;66:210-211
67. Jaffe G, Yang C, Wang X, et al. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology 1998;105:46-56
68. Hernandez C, Cetner A, Jordan J, et al. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol 2008;59:363-380
69. Early communication about an ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, and Cimzia). Available from: www.fda.gov/CDER/drug/early-comm/TNF-blockers.htm (last accessed 20 February 2009)